Publications

Export 6 results:
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Shao, Mingyuan  [Clear All Filters]
2011
Berger JS, Bhatt DL, Steg GP, Steinhubl SR, Montalescot G, Shao M, et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2011;162(1):98-105.e1. Abstract
2010
Berger PB, Bhatt DL, Fuster V, Steg GP, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the (CHARISMA) trial. Circulation. 2010;121(23):2575-83. Abstract
2009
Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak K-, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359-63. Abstract
Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg GP, Montalescot G, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009;120(23):2337-44. Abstract
Mak K-, Bhatt DL, Shao M, Hankey GJ, Easton DJ, Fox KA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;157(4):658-65. Abstract
Mak K-, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, et al. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J. 2009;30(7):857-65. Abstract